Łuczyński W, Stasiak-Barmuta A, Piszcz J, Iłendo E, Kowalczuk O, Krawczuk-Rybak M
Department of Pediatric Oncology, Medical University of Białystok, Poland.
Neoplasma. 2007;54(6):527-35.
Despite discovery of new therapeutic agents, including nucleoside analogs and monoclonal antibodies, the B-cell chronic lymphocytic leukemia (B-CLL) remains incurable. In recent years, some effort has been made in developing T-cell specific immunity against neoplasmatic cells. Reconstitution of effective costimulation and immunological response of host T-cells against CLL cells could be a potential approach in immunotherapeutic trials. CD40/CD40L system is involved in the survival and proliferation of normal and neoplasmatic B-cells. Some preclinical studies have shown that CD40 stimulation can differentiate leukemic cells into dendritic cells (DCs) and result in host response. In this study, we sought to determine whether B-CLL cells could be turned into efficient and functional antigen presenting cells, as well as to assess the type of allogeneic T-cell response against B-CLL - derived DCs.
B-CLL cells from 25 patients were cultured with or without the presence of CD40L and IL-4 for 96 hours and then cultured in mixed lymphocyte reaction with allogeneic T-cells.
our experiment confirm that B-CLL cells can be turned into dendritic-like cells, additionally, these cells express chemokines involved in T-cell migration and stimulate allogeneic response.
尽管发现了新的治疗药物,包括核苷类似物和单克隆抗体,但B细胞慢性淋巴细胞白血病(B-CLL)仍然无法治愈。近年来,人们在开发针对肿瘤细胞的T细胞特异性免疫方面做出了一些努力。重建有效的共刺激和宿主T细胞对CLL细胞的免疫反应可能是免疫治疗试验中的一种潜在方法。CD40/CD40L系统参与正常和肿瘤性B细胞的存活和增殖。一些临床前研究表明,CD40刺激可使白血病细胞分化为树突状细胞(DCs)并引发宿主反应。在本研究中,我们试图确定B-CLL细胞是否可以转化为高效且有功能的抗原呈递细胞,以及评估针对B-CLL来源的DCs的同种异体T细胞反应类型。
将25例患者的B-CLL细胞在有或无CD40L和IL-4存在的情况下培养96小时,然后与同种异体T细胞进行混合淋巴细胞反应培养。
1)CD40刺激后,B-CLL细胞实现了DCs的表型和功能特征(即共刺激分子和黏附分子在mRNA和蛋白质水平上调);2)白血病来源的DCs表达更高水平的参与T细胞迁移的趋化因子mRNA(MDC、TARC和CCR7);3)T细胞对白血病来源的DCs的增殖反应由CD4和CD8细胞组成(HLA-DR和OX40上调)。
我们的实验证实B-CLL细胞可以转化为树突状样细胞,此外,这些细胞表达参与T细胞迁移的趋化因子并刺激同种异体反应。